BCL2 and acute lymphoblastic leukemia: Similarly, other groups have demonstrated that ETP-ALL is dependent on BCL-2 [23] and that BCL-2 is a therapeutic target in ETP-ALL [23,24,26,33,34,35]; we expanded on those works by demonstrating preferential expression of BCL-2 in ETP-ALL patient samples.